Olmeblo Hct (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmeblo Hct, is an angiotensin II receptor blocker combined with a thiazide diuretic presented as a tablet for oral use. It treats hypertension, often in patients who require additional blood pressure control beyond what a single agent can provide.

GNH USA supplies Olmeblo Hct as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmeblo Hct is an antihypertensive medication that works within the renin‑angiotensin‑aldosterone system to lower elevated blood pressure. - Hypertension: helps achieve target blood pressure when monotherapy is insufficient. - Hypertensive patients with fluid retention: adds diuretic effect to improve blood pressure control. - High‑risk cardiovascular patients: contributes to overall risk reduction when combined with lifestyle measures.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Significant electrolyte imbalance (e.g., hyponatremia) - Liver function abnormalities

Before initiating Olmeblo Hct, consider the following precautions: - Renal function: assess baseline creatinine and eGFR. - Electrolytes: monitor potassium and sodium levels regularly. - Pregnancy: avoid use; drug is contraindicated in the second and third trimesters. - Concomitant NSAIDs: use with caution as they may reduce antihypertensive effect. - Gout: monitor uric acid as thiazides can precipitate attacks. Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Olmeblo Hct may interact with several drug classes; monitoring is advised.

Major Interactions (Avoid): - Lithium: increased risk of lithium toxicity. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - ACE inhibitors or other ARBs: additive effect on blood pressure and kidney function.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive response. - Antidiabetic agents: possible enhancement of hypoglycaemic effect. - Antimicrobials such as trimethoprim‑sulfamethoxazole: may affect potassium balance.